comparemela.com

Latest Breaking News On - Preclinical results - Page 1 : comparemela.com

Nano-Scale Vision Implant Promises New Hope for Blindness

Nano-Scale Vision Implant Promises New Hope for Blindness
neurosciencenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from neurosciencenews.com Daily Mail and Mail on Sunday newspapers.

Humacyte Third Quarter 2023 Financial Results and Business Update

– Positive top line results from the V005 Phase 2/3 trial of the Human Acellular Vessel™ (HAV™) in vascular trauma repair – – BLA for an indication in vascular trauma planned to be filed with the FDA during the current quarter – - Conference call and live webcast at 4:30 p.m. ET today - DURHAM, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, t

Form 10-K InMed Pharmaceuticals For: Jun 30

Form 10-K InMed Pharmaceuticals For: Jun 30
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced that the preclinical results of IBI363 were published in Nature Cancer (IF=22.7). The publication entitled, "IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells".

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.